SID 2026

HOUSTON, May 22, 2026 FibroBiologics, Inc. announced new preclinical data from its CYPS317 psoriasis program demonstrating durable immune modulation...

WAYNE, Pa., May 15, 2026 Palvella Therapeutics announced new positive Phase 2 TOIVA trial data for QTORIN™ rapamycin in...

SOUTH SAN FRANCISCO, Calif., May 7, 2026 TRexBio announced new late-breaking translational and preclinical data supporting TNFR2 agonism as...